Searched for
NCE
Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for u...- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Wockhardt shares jump 9% after strong Q4 turnaround, robust FY26 growthWockhardt shares saw a significant jump on Tuesday. The pharmaceutical company reported a strong turnaround in its March quarter performanc...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 33%To get clarity on the markets, there are three questions to which you need answers. First: When will the war end? Second: How long will it ...
- US protects genuine investors in EB-5 green card programThe US Citizenship and Immigration Services (USCIS) has updated its policy manual to protect 'good faith' investors in the EB-5 program. Th...
- Lupin to resize portfolio, slash costs in US biz turnaroundIn an interview to ET, CEO Vinita Gupta said the company had already exited a few products filed from its Somerset facility in New Jersey a...
- Suven's new chemical entity enters clinical trial stage in USPharmaceutical firm Suven Life Sciences today said its new chemical entity (NCE) has entered the phase 1 of clinical trial in the US.
- Venus Remedies hits 52-week high on DCGI nodVenus Remedies Ltd surged over 7 per cent in trade on Wednesday to hit its 52-week high of Rs 328.25 after the pharma company announced tha...
- Venus gets DCGI nod for Phase-III of cancer detection entityIn a recent report, the World Health Organisation (WHO) has warned that there will be a cancer patient in each household in India by 2020.
- Textiles ministry grants Rs 24.5 crore to ICT to set up R&D centreA textiles committee will assist ICT in organising seminars all over the country and collecting samples of various materials.
- Drug companies plan late-stage deals with MNCsIn a distinct shift in their new drug development strategy, Indian pharma majors such as Dr Reddy’s Lab (DRL), Nicholas Piramal, Wockhardt ...
- Glenmark gets domestic patent for NCEIn what is perhaps the first domestic patent for a new chemical entity (NCE) by an Indian company, drug research company Glenmark Pharmaceu...
- Pharma companies demerging NCE, NDDS operationsPharma majors are de-merging their NCE operations into separate cos to scale-up their activities and achieve better focus. Drug cos in pric...
- Ranbaxy to hive off drug discovery research bizRanbaxy Laboratories has decided to hive off its drug discovery research (DDR) operation into a separate company and plans to list the new ...
- NPIL to invest Rs 300 cr in R&D unit: Domestic pharma major Nicholas Piramal India (NPIL) has decided to invest some Rs 250-300 crore in the next two years in its recently dem...
- Ranbaxy first Indian pharma to launch NCE globallyRanbaxy has completed the second phase of the clinical trial of a revolutionary anti- malarial drug.
- Indian pharma cos close to blockbuster breakthroughIndian pharma majors may manage to market their first indi-genous "blockbuster drugs" or new chemical entities (NCEs) in the next four year...
Load More
